Clinical Trial

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-12-23; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2025-07-02
Trial Details
NCT Number NCT06756451
Lead Sponsor Nanjing RegeneCore Biotech Co., Ltd.
Conditions Hematologic Malignancies
Enrollment 71 participants
Start Date 2025-03-25
Primary Completion 2028-04-08 (estimated)
Study Completion 2028-07-14 (estimated)
Updated on ClinicalTrials.gov 2026-01-30